The (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one is a chiral oxazolidinone process intermediate used in the convergent synthesis of ezetimibe, a 2-azetidinone cholesterol absorption inhibitor. Direct formulation of this oxazolidinone as a standalone finished API is not assigned a monograph in USP, Ph. Eur., or JP; its application profile is therefore defined by the downstream ezetimibe API that is released after intramolecular cyclisation and removal of the chiral auxiliary. The (5S)-configured hydroxy-5-(4-fluorophenyl)pentanoyl side chain is retained in the final molecule, while the (4S)-4-phenyl-2-oxazolidinone auxiliary is cleaved and must be reduced to low residual levels. In production, the cyclisation and auxiliary-removal sequence is run under controlled pH and temperature because the β-lactam ring of ezetimibe is vulnerable to alkaline hydrolysis and acid-catalysed ring-opening. Jacketed reactors maintain the reaction mass below 25°C during base-mediated steps; if the jacket cooling duty is exceeded by a fast base feed, the temperature excursion above the validated upper limit increases the ring-opened ester impurity. In-process HPLC under USP <621> tracks disappearance of the starting intermediate and formation of ezetimibe-related compounds, while chiral HPLC on an amylose tris(3,5-dimethylphenylcarbamate) stationary phase separates the undesired enantiomer. The residual 4-phenyl-2-oxazolidinone content must be controlled to the limit specified in the ezetimibe drug substance filing because this auxiliary can behave as a reactive impurity in later statin combination products. Thus, the first downstream application is not a dosage form but the validated API synthesis stream that determines whether tablet, capsule, granule, or injectable investigational batches can satisfy ICH Q3A limits and compendial monographs.

Batch records for this step specify a minimum chiral purity of 99.0% area for the intermediate before cyclisation. Lower optical purity produces ezetimibe containing the corresponding enantiomeric impurity that can co-elute under certain reversed-phase conditions but is resolved by chiral HPLC. Production-scale filter dryers must be qualified for solvent removal because the intermediate retains polar aprotic solvent from the reaction mixture; residual solvents are controlled by USP <467>. When the wet cake is dried too rapidly, agglomeration occurs and the subsequent processing step becomes mass-transfer-limited, leaving unreacted intermediate that persists into the API. This equipment-related failure mode is observed when the vacuum ramp exceeds the dryer supplier's limiting curve or when the nitrogen flow is reduced below the validated range. Consequently, the intermediate is a critical quality attribute carrier for the entire downstream drug product chain.

What Limits Direct Compression of Ezetimibe Derived from This Intermediate?

Ezetimibe base released from the oxazolidinone intermediate is practically insoluble in water, and its oral absorption is dissolution-rate-limited. Direct compression of the 10-mg tablet is therefore determined less by chemical stability than by particle engineering of the API. After purification, the API is micronised by spiral jet milling to a controlled D90, typically in the 20–30 µm region. The micronised powder has low bulk density and high electrostatic charge; when transferred through gravity-fed bins, it adheres to stainless steel surfaces and can reduce blend uniformity. A direct compression formula generally contains microcrystalline cellulose as a dry binder, croscarmellose sodium as a disintegrant, sodium lauryl sulfate as a wetting agent, and magnesium stearate as a lubricant. Over-lubrication with magnesium stearate above the validated range can retard dissolution because the hydrophobic film on the micronised drug particles limits contact with the dissolution medium. The tablet blend is compressed on a rotary tablet press fitted with single-station or double-station punches; compression force must be high enough to achieve hardness above 4.0 kp for film-coating, but not so high that disintegration time exceeds the USP <701> acceptance criterion. Dissolution testing by USP <711> Apparatus II at 75 rpm is used to verify that the release profile remains within the compendial specification; if the D90 of the input API drifts above the validated upper limit, the dissolution at the first sampling point falls below the monograph Q value and the batch fails. Thus, the chiral intermediate's particle habit and residual solvent profile indirectly set the milling behaviour and the direct compression robustness.

When the tablet is film-coated, the moisture uptake of the core is controlled because the β-lactam ring of ezetimibe can hydrolyse under accelerated conditions if the core moisture is above 1.0% w/w at the start of coating. Coating pan inlet air temperature is maintained below the glass transition temperature of the pregelatinized starch component; defects such as edge chipping and picking are more common when the core hardness drops below the lower control limit due to insufficient compression force. The drug substance derived from this intermediate must meet the USP ezetimibe monograph assay limits before tableting; any unreacted oxazolidinone carried through from poor cleavage reduces the assay value and may appear as an unidentified peak in the related substances test. In production campaigns, batch-to-batch variation in the intermediate's particle size after drying has been observed to shift the milled API span, which in turn changes the tablet-to-tablet content uniformity measured by USP <905>. This is the central process conflict for direct compression.

When Ezetimibe Is Filled into Hard Capsules after Jet Milling

Hard capsule filling is selected when a 10-mg dose must be delivered without the compression stress of tableting or when clinical supplies require a simpler manufacturing route. The process conflict is segregation. Jet-milled ezetimibe with a D90 below 30 µm separates from large-particle fillers during transfer, especially if the blend is subjected to vibration on a dosator capsule machine. A tamping-pin machine is preferred over a dosator machine for low-density, cohesive powders because the tamping pins form a compacted plug inside the filling station, reducing weight variation. The capsule fill volume is constrained by the low bulk density of the micronised drug; diluents such as pregelatinized starch and lactose monohydrate are milled to a particle size range that matches the API D50 to prevent fluidisation loss. Magnesium stearate is added at low levels, typically 0.5% w/w, because higher levels can delay disintegration of the plug inside the hard gelatin shell. Disintegration testing by USP <701> is conducted on the finished capsules; if the powder plug does not break within the specified time, the dissolution profile may fail despite acceptable blend uniformity. Capsule fill weight variation is assessed by USP <905> and the content of ezetimibe is confirmed by HPLC. The capsule route exposes the API to less shear than tableting, but the lower mechanical stress may leave agglomerates from poor intermediate drying intact, which can reduce dissolution if the agglomerates are not dispersed in the dissolution medium. Therefore, the residual solvent level and drying history of the chiral intermediate influence capsule performance through agglomeration rather than chemical interaction.

In fixed-dose combination manufacturing, ezetimibe derived from this oxazolidinone intermediate is co-processed with simvastatin, atorvastatin, or rosuvastatin in bilayer or single-layer tablets. The major incompatibility is not between the parent molecules but between ezetimibe-related impurities and the acidic degradation products of the statins. When ezetimibe is formulated with simvastatin, the statin can hydrolyse to simvastatin acid under moisture and heat; the acid environment can accelerate ring-opening of the ezetimibe β-lactam if the tablet contains even trace amounts of acidic excipients or if the intermediate carry-over contains residual acid from the cyclisation step. To minimise this risk, the intermediate is specified with a low residual acid value and controlled water content, and the API is washed to remove inorganic salts before final drying. Bilayer tablet presses are operated with a first-layer tamping force low enough to maintain a distinct layer interface; high tamping forces can cause interfacial mixing, which brings the two actives into intimate contact and increases degradation product formation. The tablets are coated with an aqueous film coating, but the coating process must avoid core moisture uptake above 1.0% w/w; this is monitored by loss on drying before and after coating. Stability-indicating HPLC methods are validated under ICH Q2(R1) to separate ezetimibe, statin acid, and related compounds. The combined product must meet ICH Q3B limits for degradation products and the USP <621> related substances acceptance criteria. This fixed-dose application can only be controlled if the chiral intermediate is released with high optical purity and low oxazolidinone residue, because any reactive auxiliary remaining in the ezetimibe may form adducts with statin acids during accelerated storage. Thus, the intermediate quality is a critical raw-material attribute for combination product stability.

Wet Granulation Route for Dose-Flexible Sachet and Tablet Granules

Wet granulation is applied when the low-dose ezetimibe must be distributed in sachet granules or when a direct compression blend lacks the flow required for high-speed tableting. The API from the chiral intermediate is first suspended in a binder solution containing hydroxypropyl cellulose or povidone and sprayed onto lactose monohydrate and microcrystalline cellulose in a high-shear mixer. Granulation is performed at a controlled impeller speed and chopper speed; the endpoint is determined by torque value, granule D50, and visual consistency. The wet mass is transferred to a fluid-bed dryer where inlet air temperature is maintained below 50°C to avoid thermal degradation of the β-lactam ring. Drying continues until the loss on drying value is below 2.0% w/w by USP <731>; over-drying can produce friable granules that generate fines during subsequent milling, while under-drying can cause tablet tooling sticking and capsule shell brittleness. The dried granules are milled through a 0.8–1.0 mm screen and blended with extragranular disintegrant and lubricant. Sachet granules are filled by weight or volume; volumetric filling requires a narrow granule size distribution to achieve the label claim. Acidic buffers are avoided in the granulation liquid because ezetimibe is unstable to low pH over extended processing times; neutral or slightly alkaline aqueous binder systems provide acceptable chemical stability. Dissolution testing of the granules follows USP <711>; if the granule D90 is too coarse, dissolution is retarded, while over-milling increases fines and causes segregation during sachet filling. The granulation route is more robust than direct compression for low-dose products, but it is also more sensitive to the residual water content of the input API and the particle habit of the intermediate after drying.

On production-scale high-shear mixers, the sequence of binder addition is reversed when the API is pre-blended with the filler; adding the binder too rapidly can form large lumps that survive the mill and appear as superpotent agglomerates. Granule porosity measured by mercury intrusion is used as a quality indicator when transferring the process between pilot and commercial scales. If the pore volume is too low, disintegration time is prolonged because water cannot penetrate the granule matrix. The process is validated by demonstrating that the final blend meets USP <905> uniformity and that the dissolution profile is comparable to the reference listed drug under the conditions specified in the ezetimibe tablet monograph. Published data for sachet-specific ezetimibe monographs is limited; manufacturer-developed specifications are therefore derived from ICH Q6A and the oral powder for suspension general chapters.

Lipid Emulsion Injectables Confront a Solubility Barrier When Sourced from Oxazolidinone-Derived Ezetimibe

Injectable dosage forms of ezetimibe are not approved as commercial products, and no pharmacopoeial monograph exists for an injectable ezetimibe product. The solubility barrier is severe: the API synthesised from this intermediate is practically insoluble in water and is not ionisable within the physiological pH range, so simple pH adjustment cannot produce a solution. Injectable formulation studies have therefore used co-solvent systems containing propylene glycol and ethanol, sulfobutyl ether β-cyclodextrin complexes, or lipid microspheres. Each approach imposes a different requirement on the API quality: parenteral formulations require bacterial endotoxin control by USP <85>, sterility by USP <71>, and particulate matter by USP <788>. The oxazolidinone intermediate itself must be manufactured with a low bioburden and low endotoxin load because these attributes can carry through to the API. For lipid emulsion injectables, the API is dissolved in the oil phase before high-pressure homogenisation; residual particulate matter larger than the internal droplet size is controlled by filtration. If the API contains traces of the lipophilic 4-phenyl-2-oxazolidinone auxiliary, the impurity may partition into the oil phase and alter the zeta potential of the emulsion droplets, leading to creaming or flocculation. Published data for this specific configuration is limited; manufacturers evaluating injectable formulations must generate their own stability data under ICH Q1A and safety data under ICH Q3B for parenteral products. Because the oral dose is 10 mg, any injectable development should consider that the volume of distribution and clearance expected from oral ezetimibe may not apply by the parenteral route. The chiral intermediate therefore enters injectable development indirectly, through the purity profile of the API rather than through direct formulation of the oxazolidinone.